Table 3.
Main results of meta-analysis
| Categories | Studies | Patients | MUC4+ | HRs | 95% CI | Heterogeneity | P | |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| I-Square | Ph | |||||||
| Overall | 18 | 1933 | 663 | 1.87 | 1.58-2.23 | 28.00% | 0.13 | <0.001 |
| Cancer type | ||||||||
| Lung cancer | 2 | 214 | 41 | 1.18 | 0.13-11.05 | 80.30% | 0.024 | 0.888 |
| Colorectal cancer | 2 | 338 | 101 | 1.73 | 1.17-2.54 | 0.00% | 0.431 | 0.006 |
| Biliary tract carcinoma | 6 | 378 | 149 | 2.41 | 1.69-3.42 | 0.00% | 0.67 | <0.001 |
| Pancreatic cancer | 4 | 371 | 200 | 2.01 | 1.42-2.86 | 0.00% | 0.659 | <0.001 |
| Others | 4 | 632 | 172 | 1.22 | 0.59-2.55 | 65.00% | 0.035 | 0.589 |
| Geography | ||||||||
| Western | 7 | 812 | 257 | 1.4 | 0.84-2.33 | 54.20% | 0.041 | 0.191 |
| Asian | 11 | 1121 | 406 | 1.99 | 1.63-2.44 | 0.00% | 0.503 | <0.001 |
| Methods | ||||||||
| IHC-1G8 | 7 | 933 | 301 | 1.74 | 1.11-2.75 | 55.50% | 0.036 | 0.017 |
| IHC-8G7 | 9 | 914 | 317 | 1.93 | 1.54-2.42 | 0.00% | 0.698 | <0.001 |
| Others | 2 | 86 | 45 | 1.08 | 0.14-8.10 | 77.10% | 0.037 | 0.938 |
| Cut-off Value | ||||||||
| >5% | 9 | 1113 | 355 | 1.83 | 1.48-2.27 | 0.00% | 0.839 | <0.001 |
| Study quality | ||||||||
| High | 14 | 1333 | 506 | 1.99 | 1.66-2.39 | 0.00% | 0.738 | <0.001 |
| Low | 4 | 600 | 157 | 0.89 | 0.32-2.47 | 71.90% | 0.014 | 0.825 |
IHC-1G8: Immunohistochemistry using 1G8 clone antibody, IHC-8G7: Immunohistochemistry using 8G7 clone antibody, MUC4+: MUC4 positive patients number, Ph: PHeterogeneity; HR: hazard ratio, CI: confidence interval.